Global Hypereosinophilic Syndrome Therapeutics Pipeline Review 2016 – Research and Markets

DUBLIN–(BUSINESS WIRE)– Research and Markets has announced the addition of the « Hypereosinophilic
Syndrome – Pipeline Review, H2 2016″ report to their offering.

The Pharmaceutical and Healthcare latest pipeline guide
Hypereosinophilic Syndrome – Pipeline Review, H2 2016, provides
comprehensive information on the therapeutics under development for
Hypereosinophilic Syndrome (Hematological Disorders), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide
also reviews of key players involved in therapeutic development for
Hypereosinophilic Syndrome and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase
III and Phase II stages are 1 and 4 respectively.

Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide
helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Hypereosinophilic Syndrome Overview
3. Therapeutics Development
4. Pipeline Products for Hypereosinophilic Syndrome – Overview
5. Pipeline Products for Hypereosinophilic Syndrome – Comparative Analysis
6. Hypereosinophilic Syndrome – Therapeutics under Development by
   Companies
7. Hypereosinophilic Syndrome – Therapeutics under Investigation by
   Universities/Institutes
8. Hypereosinophilic Syndrome Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Hypereosinophilic Syndrome – Products under Development by Companies
13. Hypereosinophilic Syndrome – Products under Investigation by
    Universities/Institutes
14. Hypereosinophilic Syndrome – Companies Involved in Therapeutics
    Development

• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Knopp Biosciences LLC
• Kyowa Hakko Kirin Co Ltd
• Stemline Therapeutics Inc

For more information about this report visit http://www.researchandmarkets.com/research/pm5l2z/hypereosinophilic.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005652/en/